Tag: 6

In accordance with section 30 of the Capital Markets Act, Pandora A/S hereby announces that
BlackRock, Inc. has notified the company that it now holds 7,485,780 shares, corresponding to 9.47% of the total voting rights and share capital (previously 9.51%). Additionally, BlackRock, Inc. controls voting rights attached to financial instruments amounting to 0.50% (previously 0.49%). In total, BlackRock, Inc. control 9.98% of the company’s voting rights (previously 10.01%).

REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced positive topline results from a confirmatory efficacy study comparing AVT23 (ADL-018), a proposed biosimilar to Xolair® (omalizumab), with the reference biologic.

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG